GEMP
Gemphire Therapeutics, Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Gemphire Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics of dyslipidemia, as well as non-alcoholic fatty liver disease. It offers a small molecule formulated as a tablet product under the Gemcabene brand. The company was founded by Charles L. Bisgaier and David Lowenschuss on October 30, 2014 and is headquartered in Livonia, MI.
Market Cap: 4.46 Million
Primary Exchange: NASDAQ
Website: http://www.gemphire.com
Shares Outstanding: 14.9 Million
Float: 10.3 Million
Dividend: (%)
Beta: -0.10438226813599052
Sector: Health Technology
Industry: Pharmaceuticals: Major
Ethical Flags
Longest drawdown: 808 trading days
From: 2017-07-31 To: 2019-12-30
Lowest Point:
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|